drugset / Trial / NCT00680433

Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)

NCT00680433 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example there are reasons to believe that ketamine, also used as an anaesthetic agent, may have such protective properties. In this clinical study patients undergoing a course of ECT will be offered the opportunity to receive a small dose of ketamine (or a placebo) as part of their anaesthetic at the time of ECT treatment. Mood changes and any memory changes will be evaluated to see if the subjects who received ketamine had less memory side effects than those who did not, while still improving their depression.

Timeline

Start
2008-04
Primary completion
2012-10
Completion
2012-10

Outcome

Missed primary endpoint

paper there was no overall difference in efficacy at the end of the ECT course. PMID 22858219 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.25 mg/kg Intravenous
Subject Ketamine Small molecule 0.5 mg/kg Intravenous